Radiopharm Theranostics Limited Sponsored ADR AI Stock Analysis
Want to see RADX full AI Analyst Report?
Radiopharm Theranostics Limited Sponsored ADR (RADX) AI Stock Analysis
Radiopharm Theranostics Limited Sponsored ADR
(NASDAQ:RADX)
The score is primarily held down by weak financial performance (widening losses and rising cash burn) and bearish technicals (price far below major moving averages with negative MACD). Valuation provides limited support due to loss-making status (negative P/E) and no dividend yield data.
Radiopharm Theranostics Limited Sponsored ADR (RADX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $979.03K
- Dividend Yield
- ―
- Average Volume (3M)
- 57.95K
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 0.99
- Revenue Growth
- -19.76%
- EPS Growth
- 8.58%
- Country
- US
- Employees
- 14
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Radiopharm Theranostics Limited Sponsored ADR Business Overview & Revenue Model
Company Description
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating pro...
Radiopharm Theranostics Limited Sponsored ADR Financial Statement Overview
Summary
Despite revenue growth off a small base, profitability is severely negative with gross profit turning negative and operating losses widening. Operating cash flow remains deeply negative with increasing burn, raising funding/dilution risk. The main offsetting strength is a debt-free balance sheet, but equity declined meaningfully, reflecting ongoing losses.
Income Statement
12Very NegativeBalance Sheet
56NeutralCash Flow
18Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.76M | 2.71M | 3.63M | 299.23K | 8,831 | 292.36K |
| Gross Profit | -1.07M | -2.10M | 39.28K | 299.23K | 8,831 | 292.36K |
| EBITDA | -69.12M | -64.09M | ― | -44.21M | -17.96M | -31.24M |
| Net Income | -55.05M | -53.94M | -38.34M | -47.95M | -30.34M | -34.61M |
Balance Sheet | ||||||
| Total Assets | 60.14M | 60.14M | 86.48M | 72.04M | 83.38M | 74.95M |
| Cash, Cash Equivalents and Short-Term Investments | 4.14M | 4.14M | 29.12M | 18.58M | 26.98M | 11.70M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 37.81M | 37.81M | 43.61M | 44.68M | 20.42M | 29.37M |
| Stockholders Equity | 24.69M | 24.69M | 44.79M | 28.12M | 62.96M | 44.38M |
Cash Flow | ||||||
| Free Cash Flow | -22.26M | 0 | -36.65M | -22.98M | -38.25M | -24.73M |
| Operating Cash Flow | -54.34M | -51.63M | -36.65M | -22.98M | -9.92M | -23.20M |
| Investing Cash Flow | -5.69M | -5.30M | 1.77M | -320.00K | -28.37M | -1.53M |
| Financing Cash Flow | 35.04M | 32.65M | 45.43M | 30.20M | 65.11M | 9.22M |
Radiopharm Theranostics Limited Sponsored ADR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RADX, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.93, below the 50-day MA of 1.29, and below the 200-day MA of 3.47, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 30.97 is Neutral, neither overbought nor oversold. The STOCH value of 8.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RADX.
Radiopharm Theranostics Limited Sponsored ADR Peers Comparison
Overall Rating
ACRV52Neutral
RADX42Neutral
CELU40Underperform
SER40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | $62.14M | -0.77 | -70.14% | ― | ― | 16.04% | |
| 42Neutral | $12.76M | -0.26 | -144.24% | ― | -19.76% | 8.58% | |
| 40Underperform | $20.45M | -0.35 | 142.25% | ― | -58.14% | 47.25% | |
| 40Underperform | $36.93M | -0.79 | -195.03% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RADX | Radiopharm Theranostics Limited Sponsored ADR | 0.76 | -3.76 | -83.19% | |
| SER | Serina Therapeutics, Inc. | 1.39 | -2.43 | -63.58% | |
| CELU | Celularity Inc. | 0.63 | -0.89 | -58.55% | |
| ACRV | Acrivon Therapeutics, Inc. | 1.45 | -0.93 | -39.08% | |
| TELO | Telomir Pharmaceuticals, Inc. | 0.49 | -0.91 | -65.00% |
Radiopharm Theranostics Limited Sponsored ADR Corporate Events
Radiopharm Theranostics Publishes Four Director Interest Notices
On November 11, 2026, Radiopharm Theranostics Limited published an Australian Securities Exchange announcement titled “Change of Director’s Interest Notices x 4.” The notices reported that directors Bruce Goodwin and Ian Turner each disposed of 1,061...
Radiopharm Theranostics to Present Positive RAD101 Phase 2b Brain Metastases Data at SNO 2026
On September 14, 2026, Radiopharm Theranostics announced that interim data from its U.S. Phase 2b imaging trial of 18F-RAD101 in suspected recurrent brain metastases have been selected for a late-breaking oral presentation at the Society of Neuro-Onc...
Radiopharm Theranostics Posts Deeper FY26 Loss as R&D Spend Jumps and Cash Reserves Fall
Radiopharm Theranostics Limited has reported a sharply wider loss for the year ended 30 June 2026, as it stepped up investment in clinical development of its radiopharmaceutical pipeline. Revenue from contracts with customers fell 23.8% to $2.77 mill...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
